HomeCompareBXS vs PFE

BXS vs PFE: Dividend Comparison 2026

BXS yields 73.72% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BXS wins by $2955258703469.96M in total portfolio value
10 years
BXS
BXS
● Live price
73.72%
Share price
$28.76
Annual div
$21.20
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2955258703470.01M
Annual income
$2,947,577,713,741,642,000.00
Full BXS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BXS vs PFE

📍 BXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBXSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BXS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BXS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXS
Annual income on $10K today (after 15% tax)
$6,266.21/yr
After 10yr DRIP, annual income (after tax)
$2,505,441,056,680,396,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BXS beats the other by $2,505,441,056,680,373,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXS + PFE for your $10,000?

BXS: 50%PFE: 50%
100% PFE50/50100% BXS
Portfolio after 10yr
$1477629351735.03M
Annual income
$1,473,788,856,870,834,200.00/yr
Blended yield
99.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BXS
Analyst Ratings
7
Buy
13
Hold
Consensus: Hold
Altman Z
1.0
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXS buys
0
PFE buys
0
No recent congressional trades found for BXS or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBXSPFE
Forward yield73.72%6.13%
Annual dividend / share$21.20$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$2955258703470.01M$49.6K
Annual income after 10y$2,947,577,713,741,642,000.00$26,258.71
Total dividends collected$2954753912979.87M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: BXS vs PFE ($10,000, DRIP)

YearBXS PortfolioBXS Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$25,444$14,744.02$9,153$693.39+$16.3KBXS
2$97,346$70,120.96$8,593$849.25+$88.8KBXS
3$605,609$501,448.92$8,336$1,066.78+$597.3KBXS
4$6,479,055$5,831,053.34$8,437$1,384.80+$6.47MBXS
5$123,536,320$116,603,730.93$9,013$1,875.40+$123.53MBXS
6$4,287,859,532$4,155,675,669.98$10,306$2,680.72+$4287.85MBXS
7$274,196,617,197$269,608,607,497.71$12,820$4,101.38+$274196.60MBXS
8$32,519,027,631,835$32,225,637,251,433.38$17,673$6,826.70+$32519027.61MBXS
9$7,178,495,073,237,400$7,143,699,713,671,337.00$27,543$12,591.86+$7178495073.21MBXS
10$2,955,258,703,470,006,300$2,947,577,713,741,642,000.00$49,560$26,258.71+$2955258703469.96MBXS

BXS vs PFE: Complete Analysis 2026

BXSStock

BancorpSouth Bank provides commercial banking and financial services to individuals and small-to-medium size businesses. The company operates through Banking Services Group, Mortgage, Insurance Agencies, Wealth Management, and General Corporate and Other segments. It offers various deposit products, including interest and noninterest bearing demand deposits, and saving and other time deposits. The company also provides commercial loans, including term loans, lines of credit, equipment and receivable financing, and agricultural loans; a range of short-to-medium term secured and unsecured commercial loans to businesses for working capital, business expansion, and the purchase of equipment and machinery; and construction loans to real estate developers for the acquisition, development, and construction of residential subdivisions. In addition, it offers fixed and adjustable rate residential mortgage loans secured by owner-occupied property; residential construction loans; second mortgage loans; and home equity lines of credit, as well as non-residential consumer loans that consist of automobile, recreation vehicle, boat, personal, and deposit account secured loans, as well as issues credit cards. Further, the company operates as an agent for the sale of commercial lines of insurance; and offers a line of property and casualty, life, health, and employee benefits products and services. Additionally, it provides credit related products, trust and investment management, asset management, retirement and savings solutions, and estate planning and annuity products. It operates in Alabama, Arkansas, Florida, Louisiana, Mississippi, Missouri, Tennessee, Texas, and Illinois. The company was formerly known as BancorpSouth, Inc. and changed its name to BancorpSouth Bank in October 2017. BancorpSouth Bank was founded in 1876 and is headquartered in Tupelo, Mississippi.

Full BXS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BXS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXS vs SCHDBXS vs JEPIBXS vs OBXS vs KOBXS vs MAINBXS vs JNJBXS vs MRKBXS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.